Free Newsletter
Register for our Free Newsletters
Analysis, Inspection and Laboratory
Assisted/Independent Living
Clinical and Nursing Equipment
Design and Manufacture of Medical Equipment
Diagnostics Equipment, Monitoring and Test
Education, Training and Professional Services
Health Education and Patient Management
Health Estates Management
Healthcare Support and Information Services
Hygiene and Infection Control
IT and Communications in Healthcare
Medical Device Technology
Research and Development
Safety and Security
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone

Aethlon Medical extends cancer research studies

Aethlon Medical : 19 September, 2007  (New Product)
Further studies have been initiated by Aethlon Medical to support the use of its Hemopurifier technology in cancer care.
Aethlon recently documented that the Hemopurifier, targeted to treat drug and vaccine resistant viruses, is also effective in capturing tumour derived exosomes from the blood of cancer patients. Exosomes are particles released by solid tumors, lymphomas, and leukemia, and are known to suppress the immune response in cancer patients.

In studies led by Dr Douglas Taylor at the University of Louisville, 60 percent of circulating exosomes were removed from the blood of ovarian cancer patients during first pass (approximately 10 minutes) through a small scale Hemopurifier. The capture data was consistent over the course of five different studies.

New studies, designed to document in vitro capture of exosomes by the Hemopurifier at time intervals up to 120 minutes, are now under way. These studies will also seek to demonstrate whether the removal of circulating exosomes by the Hemopurifier diminishes the suppression of T cell proliferation and activation by the biological fluid.

The studies are being conducted by Dr Taylor, who is a recognised authority on the causative effects of immune suppression in cancer patients. He is credited with the initial characterization of exosomes and is a leading peer reviewed author on the subject. Initial data resulting from these studies is expected to be available in early October 2007.

'Reversing the immune suppression in cancer patients is an unmet medical need likely to increase patient responsiveness to established cancer therapies,' stated Aethlon chairman and CEO, James A Joyce. 'Supporting data that demonstrates our capture of exosomes can reduce immune suppression, would immediately elevate the status of the Hemopurifier as a potential adjuvant therapy in the $43 billion cancer treatment market.'
Bookmark and Share
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
   © 2012
Netgains Logo